These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9143703)

  • 1. Role of complement in HIV infection.
    Stoiber H; Clivio A; Dierich MP
    Annu Rev Immunol; 1997; 15():649-74. PubMed ID: 9143703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV and human complement: inefficient virolysis and effective adherence.
    Bánki Z; Stoiber H; Dierich MP
    Immunol Lett; 2005 Mar; 97(2):209-14. PubMed ID: 15752560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV and complement: hijacking an immune defense.
    Datta PK; Rappaport J
    Biomed Pharmacother; 2006 Nov; 60(9):561-8. PubMed ID: 16978830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
    Zhou J; Montefiori DC
    Virology; 1996 Dec; 226(1):13-21. PubMed ID: 8941318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
    Sullivan BL; Knopoff EJ; Saifuddin M; Takefman DM; Saarloos MN; Sha BE; Spear GT
    J Immunol; 1996 Aug; 157(4):1791-8. PubMed ID: 8759769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement.
    Marschang P; Sodroski J; Würzner R; Dierich MP
    Eur J Immunol; 1995 Jan; 25(1):285-90. PubMed ID: 7531147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-opsonized HIV: the free rider on its way to infection.
    Stoiber H; Pruenster M; Ammann CG; Dierich MP
    Mol Immunol; 2005 Feb; 42(2):153-60. PubMed ID: 15488605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement receptors in HIV infection.
    Doepper S; Kacani L; Falkensammer B; Dierich MP; Stoiber H
    Curr Mol Med; 2002 Dec; 2(8):703-11. PubMed ID: 12462391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis.
    Spear GT; Sullivan BL; Takefman DM; Landay AL; Lint TF
    Immunology; 1991 Aug; 73(4):377-82. PubMed ID: 1916889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus and the complement system.
    Gras G; Legendre C; Richard Y; Dormont D
    Exp Clin Immunogenet; 1997; 14(1):11-5. PubMed ID: 9187917
    [No Abstract]   [Full Text] [Related]  

  • 15. Diminished expression of cell-surface complement regulatory proteins in HIV-infected children and with HIV infection of peripheral blood mononuclear cells in vitro.
    Jarvis JN; Taylor H; Long PM; Gutta PV; Pousak T; Fine N
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):249-56. PubMed ID: 7540489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV and human complement: mechanisms of interaction and biological implication.
    Dierich MP; Ebenbichler CF; Marschang P; Füst G; Thielens NM; Arlaud GJ
    Immunol Today; 1993 Sep; 14(9):435-40. PubMed ID: 8216721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV and complement: role of the complement system in HIV infection.
    Marschang P; Ebenbichler CF; Dierich MP
    Int Arch Allergy Immunol; 1994; 103(2):113-7. PubMed ID: 8292898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients.
    Gerencer M; Burek V; Crowe BA; Barrett NP; Dorner F
    Microb Pathog; 1998 Nov; 25(5):253-66. PubMed ID: 9878454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference with complement regulatory molecules as a possible therapeutic strategy in HIV infection.
    Pintér C; Beltrami S; Stoiber H; Negri DR; Titti F; Clivio A
    Expert Opin Investig Drugs; 2000 Feb; 9(2):199-205. PubMed ID: 11060671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.